文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

异氟烷镇静在接受静脉-动脉体外膜氧合治疗的心源性休克患者中的应用——一项观察性倾向匹配研究

Isoflurane Sedation in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation Treatment for Cardiogenic Shock-An Observational Propensity-Matched Study.
PubMed 文献 · Crit Care Explor · 2020-03-24
一句话结论在静脉-动脉体外膜氧合治疗的心源性休克患者中,异氟烷挥发性镇静可行且不增加儿茶酚胺剂量或体外膜氧合流量,但费用更高。

该回顾性单中心研究纳入2018年11月至2019年10月接受静脉-动脉体外膜氧合治疗的32例心源性休克患者使用异氟烷镇静,并与2013年1月至2018年11月心源性休克登记中静脉镇静患者按1:1倾向评分匹配。异氟烷组静脉镇静药物使用更少(86% vs 32%;p=0.01),平均心率较低(85.2±20.5 vs 74.7±15.0次/分;p=0.02),平均收缩压、儿茶酚胺剂量、体外膜氧合血流量和气流量、通气时间、出血并发症及30天死亡率两组相似。异氟烷组人均镇静费用显著更高(537±624 vs 1280±837欧元;p<0.001)。作者认为异氟烷挥发性镇静可行,但费用更高。

要点

  • 在静脉-动脉体外膜氧合治疗的心源性休克患者中,异氟烷镇静可行,且不增加儿茶酚胺剂量或体外膜氧合流量。
  • 异氟烷组静脉镇静药物使用更少(86% vs 32%;p=0.01),平均心率更低(85.2±20.5 vs 74.7±15.0次/分;p=0.02)。
  • 两组平均收缩压、通气时间、出血并发症(BARC 3a或以上)及30天死亡率相似。
  • 异氟烷组人均镇静费用显著更高(537±624 vs 1280±837欧元;p<0.001)。

适用人群与场景

  • 接受静脉-动脉体外膜氧合治疗的心源性休克患者。
  • 异氟烷组为2018年11月至2019年10月接受挥发性异氟烷镇静的患者;对照组为2013年1月至2018年11月心源性休克登记中静脉镇静患者,按1:1倾向评分匹配。

研究设计与关键结果

  • 回顾性单中心研究,异氟烷镇静组32例,与静脉镇静组按1:1倾向评分匹配。
  • 异氟烷组静脉镇静药物使用更少(86% vs 32%;p=0.01)。
  • 平均收缩压相似(94.3±12.6 vs 92.9±10.5 mm Hg;p=0.65),但常规镇静组平均心率显著更高(85.2±20.5 vs 74.7±15.0次/分;p=0.02)。
  • 儿茶酚胺剂量、体外膜氧合血流量和气流量、通气时间(304±143 vs 398±272小时;p=0.16)、出血并发症(BARC 3a或以上,59.3% vs 65.3%;p=0.76)及30天死亡率(59.2% vs 63.4%;p=0.80)两组相似。
  • 异氟烷组人均镇静费用显著更高(537±624 vs 1280±837欧元;p<0.001)。

证据类型、等级与局限

  • 证据类型:回顾性单中心观察性倾向匹配研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在静脉-动脉体外膜氧合治疗的心源性休克患者中,异氟烷挥发性镇静可行,但费用更高,且与静脉镇静相比不增加儿茶酚胺剂量或体外膜氧合流量。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: The feasibility and hemodynamic effects of isoflurane sedation in cardiogenic shock in the presence of venoarterial extracorporeal membrane oxygenation treatment are currently unknown.

DESIGN: Retrospective single-center study.

SETTING: Cardiac ICU of Munich university hospital.

PATIENTS/SUBJECTS: Cardiogenic shock patients with venoarterial extracorporeal membrane oxygenation treatment under sedation with volatile isoflurane between November 2018 and October 2019 have been enrolled in this study and were matched by propensity score in a 1:1 ratio with IV sedated patients treated between January 2013 and November 2018 from the cardiogenic shock registry of the university hospital of Munich.

MEASUREMENTS AND MAIN RESULTS: Isoflurane sedation was used in 32 patients with cardiogenic shock and venoarterial extracorporeal membrane oxygenation treatment. The mean age of conventionally sedated patients was 58.4 ± 13.8 years and 56.3 ± 11.5 years for patients with isoflurane sedation (p = 0.51). Administration of isoflurane was associated with lower IV sedative drug use during venoarterial extracorporeal membrane oxygenation treatment (86% vs 32%; p = 0.01). Mean systolic arterial pressure was similar (94.3 ± 12.6 vs 92.9 ± 10.5 mm Hg; p = 0.65), but mean heart rate was significantly higher in the conventional sedation group, when compared with the isoflurane group (85.2 ± 20.5 vs 74.7 ± 15.0 beats/min; p = 0.02). Catecholamine doses, venoarterial extracorporeal membrane oxygenation blood and gas flow, ventilation time (304 ± 143 vs 398 ± 272 hr; p = 0.16), bleeding complications bleeding academic research consortium 3a or higher (59.3% vs 65.3%; p = 0.76), and 30-day mortality (59.2% vs 63.4%, p = 0.80) were similar in both groups. The overall sedation costs per patient were significantly lower in the conventional group, when compared with the isoflurane group (537 ± 624 vs 1280 ± 837 €; p < 0.001).

CONCLUSIONS: Volatile sedation with isoflurane is feasible-albeit at higher costs-in patients with cardiogenic shock and venoarterial extracorporeal membrane oxygenation treatment and was not associated with higher catecholamine dosage or extracorporeal membrane oxygenation flow rate compared with IV sedation.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Scherer C, Kupka D, Stocker TJ, et al. Isoflurane Sedation in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation Treatment for Cardiogenic Shock-An Observational Propensity-Matched Study. Crit Care Explor. 2020. PMID: 32259109. doi:10.1097/CCE.0000000000000086

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。